Liver Immune Tolerance Marker Utilization Study

Immunosuppression Clinical Trial

— LITMUS  

Official title:

Liver Immune Tolerance Marker Utilization Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02541916
• Other study ID #: Tol002
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: May 31, 2021

Study information

• Verified date: September 2021
• Source: University of Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to validate and test a tolerance gene expression profile for the identification of operationally tolerant liver transplant recipients, allowing for the successful withdrawal of immunosuppression without rejection in these patients.

Description:

Previous pre-clinical work in the Levy Lab identified a novel biomarker gene set for the identification of tolerance in murine models of rapamycin-induced cardiac tolerance and spontaneous hepatic tolerance. Validation of this gene expression tolerance biomarker in operationally tolerant patients is now required for its implementation in the clinical setting. This proposal intends to validate and test our pre-clinically established tolerance gene expression biomarker in the clinical setting in order to translate our findings into improving the length and quality of life of transplant patients in the clinic.

The investigators hypothesize that a distinct gene expression profile expressed in the peripheral blood will identify operationally tolerant liver transplant recipients, allowing for the successful withdrawal of immunosuppression in these patients. Our study aims are: (I) To validate the pre-clinical gene expression profile for the identification of operationally tolerant liver recipients in plasma peripheral blood mononuclear cells (PBMCs) (2) To determine that the gene expression profile in the PBMCs is the same as the intra-graft gene expression profile (3) To demonstrate that liver transplant recipients with the tolerant gene expression profile can be safely weaned off of immunosuppression.

This proof of principle study will be conducted in two phases at the Toronto General Hospital (TGH) Phase 1 will address study aims 1 and 2, and phase 2 will address study aim 3. Potential participants will be screened and selected following predefined eligibility criteria. Eligible participants will undergo an informed consent process. The primary goal of this study is to validate the pre-clinical tolerant gene expression profile that will allow for the identification of tolerant liver recipients and for the monitored weaning off immunosuppression in these tolerant patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: May 31, 2021
• Est. primary completion date: May 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• To be eligible to participate in this study, patients must:

1. Be between 18 and 65 years of age.

2. Be recipients of a hepatic allograft.

3. Be less than 3 months post-transplant and be experiencing rejection, or be a minimum of 3 months post-transplant with or without presently experiencing rejection.

4. Be healthy live liver donors

Exclusion Criteria:

• Patients with the following conditions may not participate in the study:

1. Patients under the age of 18 and over the age of 65.

2. Patients who are positive for Human Immunodeficiency Virus (HIV),

3. Patients who have detectable levels of HCV RNA, and HBV DNA, at the time of enrollment.

4. Patients who have a combined transplant and/or have been re-transplanted.

5. Patients taking immunosuppression for other diseases besides their liver transplant.

6. Patients unable to give written informed consent in accordance with research ethics board guidelines.

Related Conditions & MeSH terms

• Immune Tolerance
• Immunosuppression

Intervention

Other:
• Controlled weaning of immunosuppression
At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.

Locations

Country	Name	City	State
Canada	Toronto General Hospital	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Validation of Tolerance Gene Expression Profile	The primary endpoint of this study is the identification and validation of a unique tolerance gene expression profile, consisting of a 6 gene profile, in 3-6 operationally tolerant patients compared to 25 rejecting and 25 healthy controls.	Enrollment to one year post cessation of immunosuppression
Secondary	Tolerance gene expression profile in graft versus peripheral blood mononuclear cells (PBMCs)	This endpoint will be defined as the ratio of patients (n=55) that will express the tolerance gene expression profile in the liver graft versus in the peripheral blood mononuclear cells.	Enrollment to one year post cessation of immunosuppression
Secondary	Test of tolerance gene expression profile	This endpoint will assess whether the tolerance gene expression profile can be successfully used to select immunosuppressed patients for the successful weaning off immunosuppression. This endpoint will be evaluated using the number of successful immunosuppression-weaned patients from a 7-10 patient cohort. Successful immunosuppression-weaned patients are defined as patients who achieve an immunosuppression free state without any histological or clinical evidence of rejection for a minimum of 1 year.	Enrollment to one year post cessation of immunosuppression